Whole Foods Market, Inc. (NASDAQ: WFM) may have just telegraphed the peak of the growth trends in organic and high-priced groceries. For years we have argued that investors need to think of Whole foods as a luxury goods destination rather than being in an industry dominated by low-margin supermarket stores. Now Whole Foods is finding again that growing pains come in measured steps, and the trends elsewhere may have even started catching up to the company.
In the latest quarterly earnings report, Whole Foods showed that same-store sales were up a mere 5.9%. That is great for other chains, but investors demand more of this luxury food giant.
The latest quarterly earnings came to $121 million, or $0.32 per share. Revenue growth was only 2% to $2.98 billion. We had estimates pegged at $0.31 in earnings per share, but the revenue expectations were $3.04 billion. That 2% sales growth was represented as being from the 13-week period last year and an increase of 11% on a comparative 12-week basis, so growth is perhaps better than it sounds on the surface.
10 Best Oil Stocks To Watch For 2015: Dun & Bradstreet Corp (DNB)
The Dun & Bradstreet Corporation (D&B), incorporated on April 25, 2000, is the source of commercial information and insight on businesses, enabling customers to Decide with Confidence. As of December 31, 2012, the Company�� global commercial database contained more than 220 million business records. The database is enhanced by its DUNSRight Quality Process, which transforms commercial data into valuable insight which is the foundation of its global solutions. Customers use D&B Risk Management Solutions to mitigate credit and supplier risk, increase cash flow and drive profitability; D&B Sales & Marketing Solutions to provide data management capabilities that provide marketing solutions to increase revenue from new and existing customers, and D&B Internet Solutions to convert prospects into clients by enabling business professionals to research companies, executives and industries.
The Company operates in three segments: North America (which consists of its operations in the United States and Canada); Asia Pacific (which primarily consists of its operations in Australia, Greater China, India and Asia Pacific Worldwide Network), and Europe and other International Markets (which primarily consists of its operations in the United Kingdom, the Netherlands, Belgium, Latin America and its European Worldwide Network). The Company conducts its business internationally through its wholly owned subsidiaries, majority-owned joint ventures, independent correspondents, strategic relationships through its D&B Worldwide Network and minority equity investments.
Risk Management Solutions
The Company provides traditional, value-added and supply management solutions. The Company�� Traditional Risk Management Solutions, which primarily includes its core DNBi product line, as well as reports from its database which are used primarily for making decisions about new credit applications, constituted 74% of its Risk Management Solutions revenue and 47% of its total revenue for the ye! ar ended December 31, 2012. Its Value-Added Risk Management Solutions, which constituted 20% of its Risk Management Solutions revenue and 12% of its total revenue for the year ended December 31, 2012, generally support automated decision-making and portfolio management through the use of scoring and integrated software solutions. The Company�� Supply Management Solutions, which can help companies understand the financial risk of their supply chain, constituted 6% of its Risk Management Solutions revenue and 4% of its total revenue in 2012. Risk Management Solutions accounted for 63% of its total revenue in 2012.
Effective January 1, 2013, the Company began managing and reporting its North America Risk Management Solutions business as DNBi subscription plans, Non-DNBi subscription plans, and projects and other risk management solutions.
The Company�� principal Risk Management Solutions are DNBi, various business information reports, eRAM, and D&B Direct. DNBi is the Company�� interactive, customizable online application that offers customers a subscription based real time access to its complete and up-to-date global DUNSRight information, comprehensive monitoring and portfolio analysis. It is also focused on helping more customers protect their business from risk through additions of DNBi products: DNBi Corporate, offering flexible pricing options allowing credit departments of all sizes to get data and options they need and Portfolio Risk Manager for DNBi, a module which allows DNBi users to create strategic one -click analytic reports to see risk and opportunity across their customer base. Various business information reports include Business Information Report, its Comprehensive Report, and its International Report that are consumed in a transactional manner across multiple platforms, such as DNB.com. eRAM is an enterprise solution for large global and domestic customers for automated decisioning and portfolio analytics. D&B Direct is a software application programming inter! face (API! ) that enables data integration inside enterprise applications, such as ERP, and enables master data management.
Sales & Marketing Solutions
The Company�� Sales & Marketing Solutions is a customer solution set, which accounted 29% of its total revenue in 2012. Within this customer solution set, it offers traditional and value-added solutions. Its Traditional Sales & Marketing Solutions generally consist of its marketing lists and labels used by the Company�� customers in direct mail and marketing activities, its education business and its electronic licensing solutions. These solutions constituted 30% of its Sales & Marketing Solutions revenue and 9% of its total revenue in 2012. Effective January 1, 2013, The Company began managing and reporting its Internet Solutions business as part of its Traditional Sales & Marketing Solutions set. Its Value-Added Sales & Marketing Solutions generally include decision-making and customer information management solutions, including data management solutions like Optimizer (its solution to cleanse, identify and enrich its customers' client portfolios) and products introduced as part of its Data-as-a-Service (DaaS) Strategy, which integrates the Company�� data directly into the applications and platforms that its customers use every day. The Value-Added Sales & Marketing Solutions constituted 70% of Sales & Marketing Solutions revenue and 20% of its total revenue in 2012
Internet Solutions
The Company�� Internet Solutions business provides organized and easy-to-use products that address the online sales and marketing needs of professionals and businesses, including information on companies, industries and executives. Internet Solutions, primarily representing the results of its Hoover's business, accounted for 7% of its total revenue in 2012. Effective January 1, 2013, the Company began managing and reporting its Internet Solutions business as part of its Traditional Sales & Marketing Solutions set.
T! he Company competes with Equifax, Inc., Experian Information Solutions, Inc., infoGROUP, Graydon, and Sinotrust.
Advisors' Opinion:- [By Geoff Gannon] d a few good businesses but Moody's was a great business. And it was splitting up.
And then he goes on to talk about how he can't evaluate management at Moody's because it is such a great business that it is hard to know whether management is any good when you put someone in charge of a business like that.
He focused on the idea of pricing power. At the Buffalo Evening News he focused on the fact that they were the dominant weekday paper and they weren't doing a Sunday edition. He knew they could knock their competitor out if they went ahead with a Sunday paper. He knew how important that was to a newspaper's economics.
Doing a common sense qualitative analysis ��like a reporter on a news story ��is what can give you these insights. For example, Quan recently wrote a blog post where he casually mentions that Games Workshop ��a small U.K. company ��raises prices every June. It is an annual ritual for them. Just like at See's Candies.
If you remember my discussion of George Risk (RSKIA), one of the things I said was that I knew George Risk's materials cost was higher than some competitors' selling price. The fact that any company could survive under conditions like that immediately suggested that dollars paid for the product was not the key concern for this product.
Perceived costs had to involve other concerns like customization, shipping speed, reliability, etc. Because it was a low cost product going into a higher cost product going into very high cost projects it seemed likely there was the opportunity to raise prices if needed. And that's what they ended up doing. The important clue for me in that investigation was the severe cost disadvantage George Risk had. You couldn�� compete at such a cost disadvantage unless price was less important than I initially thought.
I think you will find that most of these insights are not available in the financial statements. They come from reading the 10-Ks of all companies in the
- [By Jake L'Ecuyer]
Dun & Bradstreet (NYSE: DNB) was down, falling 9.16 percent to $96.71 after the company reported downbeat Q4 earnings.
Commodities
In commodity news, oil traded up 0.80 percent to $97.20, while gold traded down 0.41 percent to $1,254.50. - [By Geoff Gannon] ly doesn�� need working capital even when it grows say 3% a year or so. And some companies always need a ton of working capital like Lakeland (LAKE) or ADDvantage (AEY). How you feel about how those companies use working capital has a lot to do with whether or not you like those stocks long-term.
Then there are companies that have increased working capital very, very fast over the last decade or so ��but they��e also increased sales at a startling clip.
That�� Carbo.
Let�� look at where the difference between EBITDA and operating cash flow is coming from.
Cash flow from others as shown on GuruFocus�� 10-year financials page for Carbo ��I��l use this as a proxy for working capital changes ��was positive in only two years. And not by much. Usually, it�� been negative. Over the 10 years, that single line has added up to a negative $173 million. Wow.
Okay. Then there�� the difference between free cash flow and owner earnings. Owner earnings as you��l remember is Warren Buffett�� calculation of what a business could pay out to owners in cash at the end of the year ��if it stopped growing. But didn�� shrink. More on that later. For now, let�� look at the difference between Carbo�� depreciation and Carbo�� spending on property, plant and equipment.
Over the last 10 years, cap-ex has been: $546 million (or $425 million if you allow cap-ex to provide cash flow in certain years, this is a weird issue I don�� want to touch right now)
And over the last 10 years, depreciation has been: $201.52 million
That�� a big gap. We��e got some combination of Carbo underreporting economic depreciation by anywhere from $225 million to $350 million or so ��or we��e got Carbo investing something like $225 million to $350 million in growth.
Which is it?
Let�� check the growth angle first.
Over the last 10 years, Carbo has grown total sales by just under 18% a year. Now, I happen to
- [By Geoff Gannon] nflation plus population growth: CEC Entertainment (CEC)
路 Nominal GDP Growth: Village Supermarket (VLGEA)
Over the last 10 years ��population growth, inflation, and real output per person growth has been so low it�� hard to tell the difference between companies growing at the rate of inflation, along with the population, or along with the economy.
You have to squint really hard to see any difference in the revenue growth records of DNB, Chuck E. Cheese, and Village.
This will not be true in all countries and at all times.
A literally no growth company like Earthlink is actually shrinking. It just happens to look like it�� staying perfectly flat because inflation is hiding the company�� real decay rate. In real terms, the company has been shrinking by about 3% a year for the last 10 years. So, Earthlink is not a no growth company. It�� shrinking.
That�� a bad sign. And, frankly, I don�� know how to value Earthlink. You would need to evaluate it as a turnaround or something ��not as a business that�� simplly stuck in place. I don�� know how to do that.
So, Earhtlink goes into the ��oo hard��pile.
Dun & Bradstreet and CEC Entertainment are actual no growth businesses. This is hidden by their constant share buy backs. So, if you look at their earnings per share growth they look kind of like Peter Lynch�� idea of a ��low growth��company or even a ��talwart�� They aren��. They��e no growth businesses.
The same is pretty much true with Village Supermarket. Although this is complicated. The nature of their business ��high volume, low cost groceries ��means they can appear to be a no growth business when they are actually just keeping prices down and increasing volume. You would need to check their sales numbers more carefully. Grocery stores often discuss inflation in their annual reports. Village Supermarket always does this.
(The annual report is Exhibit 13 of the
5 Best Supermarket Stocks To Buy For 2014: QUALCOMM Incorporated(QCOM)
QUALCOMM Incorporated engages in the development, design, manufacture, and marketing of digital wireless telecommunications products and services. The company operates in four segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), Qualcomm Wireless and Internet (QWI), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies code division multiple access (CDMA)-based integrated circuits and system software for wireless voice and data communications, multimedia functions and global positioning system products. The QTL segment grants licenses to use portions of its intellectual property portfolio comprising patent rights useful in the manufacture and sale of wireless products, such as products implementing cdmaOne, CDMA2000, WCDMA, CDMA TDD, GSM/GPRS/EDGE, and/or OFDMA standards and their derivatives The QWI segment consists of Qualcomm Internet Services that provides content enablement services for the wireless industry and pu sh-to-talk and other products and services for wireless network operators; Qualcomm Government Technologies, which offers development, hardware, and analytical services to the United States government agencies involving wireless communications technologies; Qualcomm Enterprise Services that provides satellite and terrestrial-based two-way data messaging, position reporting, wireless application services, and managed data services to transportation and logistics companies and other enterprise companies; and Firethorn, which builds and manages software applications that enable mobile commerce services. The QSI segment makes strategic investments to support the worldwide adoption of CDMA- and OFDMA-based technologies and services. QUALCOMM Incorporated primarily operates in China, South Korea, Taiwan, Japan, and the United States. The company was founded in 1985 and is based in San Diego, California.
Advisors' Opinion:- [By Dan Caplinger]
But Intel has taken aim at the smartphone and mobile market, and although it's been slow out of the gate, it has some advantages over its rivals. ARM Holdings (NASDAQ: ARMH ) has gathered a client list that features most of the primary device-makers in the world, and its architecture has largely been accepted as the mobile standard. But Intel's investment in mobile manufacturing will result in smaller chips, with 22-nanometer design displacing its competitors' products. Qualcomm (NASDAQ: QCOM ) is widely seen as the leading-edge chip designer, but its current designs are based on 28-nanometer models. Intel has a huge opportunity to use its technological prowess to take a big step forward.
5 Best Supermarket Stocks To Buy For 2014: iMD Companies Inc (ICBU)
IMD Companies, Inc., formerly Optimum Mobile Imaging, Corp, incorporated in 1993, is focused on products and services in the health and fitness nutraceutical and medical diagnostics services markets. The Company provides mobile Ultrasound imaging services. It also provides Echocardiography and Vascular Ultrasound services, including Carotid, Arterial with ABI (ankle-brachial index) and Venous duplex ultrasound. The equipment will be transported into customer's facility on a medical cart by its technologist who will perform all tests in one of customer's exam rooms. In February 2011, the Company completed the acquisition of Integrated Medical Diagnostics, Inc. In January 2014, the Company announced that it has formed a partnership with Anything Technologies Media Inc. by acquiring 51% interest in R-Quest Hydroponics, Inc., developer of the environmental master controller for medical and recreational marijuana hydroponic gardens. In January 2014, IMD Companies Inc and Anything Technologies Media Inc announced that they jointly acquired Green Linx Inc., and will split revenue on a 50:50 basis.
MyLab30 by Biosound implements phased array technology for cardiac imaging, linear array for vascular and small parts imaging, as well as curved array and microconvex for general imaging. The system allows for the evaluation of the heart, vasculature and organs of the body with the appropriate transducer technology and the appropriate measurement and analysis packages.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Frontier Beverage Company Inc (OTCMKTS: FBEC), IMD Companies Inc (OTCMKTS: ICBU) and Dmh International Incorporated (OTCBB: DMHI) were all mimicking the Titanic last Friday by sinking 41.18%, 32.5% and 28.16%, respectively, last Friday. Moreover, all three of these stocks have been the subject of paid promotions or investor relation campaigns. With the promotions in mind, is it to late to dump these small cap stocks or will this week present a buying opportunity? Here is a closer look:
5 Best Supermarket Stocks To Buy For 2014: Mast Therapeutics Inc (MSTX)
Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., incorporated in December 1995, is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. As of December 31, 2011, the Company also is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel. The Company offers ANX-188 (purified poloxamer 188), ANX-514 (docetaxel for injectable emulsion) and Exelbine (vinorelbine injectable emulsion). In April 2011, the Company acquired SynthRx, Inc. In February 2014, Mast Therapeutics Inc completed its acquisition of Aires Pharmaceuticals, Inc. Aires became a wholly-owned subsidiary of Mast Therapeutics.
ANX-188 (purified poloxamer 188)
ANX-188 is an aqueous solution of a purified form of poloxamer 188. Poloxamer 188 (P1880, is a nonionic, block copolymer that has been found to improve microvascular blood flow by reducing viscosity, particularly under low shear conditions, and by reducing adhesive frictional forces. The Company�� purified form of P188 (purified P188), which is the active ingredient in ANX-188, was designed to eliminate certain low molecular weight substances present in P188 (non-purified), which is primarily responsible for the moderate to moderately severe elevations in serum creatinine levels (acute renal dysfunction) observed in prior clinical studies of P188 (non-purified). Purified P188 has been evaluated in multiple clinical studies by a prior sponsor, including a 255-patient, phase III study.
ANX-514 (docetaxel for injectable emulsion)
ANX-514 is a detergent-free emulsion formulation of docetaxel, an intravenously-injected chemotherapy drug commonly used to treat solid tumors. Taxotere, a branded form! ulation of docetaxel, is approved to treat breast, non-small cell lung, prostate, gastric, and head and neck cancers. ANX-514 was designed to have clinically comparable release of docetaxel relative to Taxotere while eliminating the presence of polysorbate 80 and ethanol, both of which are used to solubilize docetaxel in the Taxotere formulation. The ANX-514 formulation solubilizes docetaxel using oil droplets consists of a combination of non-toxic excipients. Docetaxel is contained within these oil droplets and can be administered intravenously without using detergents as pharmaceutical vehicles. Once in central circulation, the emulsion is metabolized rapidly, leaving chemically-identical active ingredient to exert its cytotoxic effect. ANX-514 may reduce the incidence and severity of hypersensitivity reactions and delay the onset of fluid retention.
Exelbine (vinorelbine injectable emulsion)
Exelbine is an emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the United States to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer.
In August 2011, the Company received a complete response letter from the Food and Drug Administration (FDA) stating that it could not approve the Exelbine Non Disclosure Agreement (NDA) in its present form and that the bioequivalence study would need to be repeated because the authenticity of the drug products used in the bioequivalence trial could not be verified in accordance with FDA standards. However, the Company elected to discontinue independent development of Exelbine and as of December 31, 2011, the Company was seeking a partner or outside investor for the program to complete the necessary bioequivalence study.
The Company competes with GlaxoSmithKline, Provenge and Pfizer.
Advisors' Opinion:- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
- [By Roberto Pedone]
Mast Therapeutics (MSTX), a biopharmaceutical company, focuses on developing therapies for serious or life-threatening diseases. This stock closed up 2.1% 65 cents per share in Thursday's trading session.
Thursday's Range: $0.63-$0.67
52-Week Range: $0.40-$1.10
Thursday's Volume: 1.11 million
Three-Month Average Volume: 1.88 millionFrom a technical perspective, MSTX spiked modestly higher here right above its 50-day moving average of 61 cents per share with decent upside volume. This stock has been trending sideways and consolidating for the last month, with shares moving between 60 cents on the downside and 72 cents on the upside. Shares of MSTX are now starting to push higher and into range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern. That trade will hit if MSTX manages to clear some near-term overhead resistance levels at 68 to 72 cents per share with high volume.
Traders should now look for long-biased trades in MSTX as long as it's trending above some key near-term support at 60 cents per share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.88 million shares. If that breakout materializes soon, then MSTX will set up to re-test or possibly take out its next major overhead resistance levels at 80 to 85 cents per share, or even 93 cents per share.
- [By James E. Brumley]
A little over a month ago, owning Mast Therapeutics, Inc. (NYSE: MSTX) was nothing but pure misery. Shares plunged from $0.63 to $0.43 in one day, when details of a dilutive public offering were unveiled. As is so often the case though, the market may have overshot with the selling effort that KO's MSTX. Though putting more shares 'out there' mathematically meant existing shareholders would have to share more of the company's upside with newcomers, what's slowly coming to light is that the inflow of new cash is still more advantageous to those prior shareholders; the company would progress little without it.
- [By Lauren Pollock]
Mast Therapeutics Inc.(MSTX) said the U.S. Food and Drug Administration gave orphan-drug designation to its MST-188 drug for the treatment of acute limb ischemia, providing a boost for the biopharmaceutical firm. Shares surged.
No comments:
Post a Comment